Merck & Co stock forecast: Third-party projections
Merck (MRK) last traded at $86.98 as of 10:50am (UTC) on 29 October 2025, moving near the lower end of its intraday range between $86.81 and $88.05. Client sentiment on the Capital.com platform shows 97.62% of positions are long, while 2.38% are short, indicating a strong buyer skew.
Past performance is not a reliable indicator of future results.
Recent Merck share price movements current price action comes ahead of the company’s upcoming earnings release, with market focus on recent sector movements, pipeline updates and key oncology product performance. Investors are reviewing Q2 results, which showed a modest revenue decline offset by growth in leading therapies, while trading volumes remain slightly below historical averages as markets adopt a cautious stance before the quarterly update (Yahoo Finance, 27 October 2025).
Merck stock forecast: Analyst price target view
Long Forecast (independent model)
Longforecast.com projects an average Merck share price of $87.34 for October 2025, rising to $95.81 by December. Its methodology is based on technical analysis and historical volatility, following recent sector trends and earnings updates as of 28 October 2025 (Long Forecast, 28 October 2025).
Stock Analysis (consensus aggregator)
StockAnalysis.com reports a 14-analyst average 12-month price target of $105.14, with estimates ranging from $85 to $122, as of 27 October 2025. The analysis highlights steady prescription demand and strength in oncology franchises, while noting ongoing sector headwinds (Stock Analysis, 27 October 2025).
Benzinga (wire compilation)
Benzinga cites a consensus price target of $116.70, based on the latest assessments from 28 institutional analysts, with projections between $85 and $155 as of 27 October 2025. The range reflects varying confidence in Merck’s new product launches and pipeline performance in the second half of the year (Benzinga, 27 October 2025).
TipRanks (aggregate broker ratings)
TipRanks records a $94.91 average 12-month price target, within a range of $82 to $120, based on 11 Wall Street analyst views as of late October 2025. The figures incorporate revisions following recent quarterly results and adjusted expectations for sector growth (TipRanks, 27 October 2025).
Analyst targets for Merck in late 2025 cluster between $95 and $116, citing product momentum and sector resilience, though forecasts remain widely spread due to pipeline uncertainties and recent earnings variability.
Analyst forecasts may differ significantly, and past performance is not a reliable indicator of future results.
MRK stock price: Technical overview
Merck (MRK) last traded at $86.98 as of 10:50am UTC on 29 October 2025, holding above its 20-, 50-, 100- and 200-day simple moving averages (SMAs) at 86.98, 84.57, 82.89 and 84.72 respectively. This alignment keeps the near-term trend constructive, with all four SMAs positioned below or near the current price, and the 20-over-50 configuration remaining intact. The 200-day exponential moving average (EMA) stands slightly higher at $87.41, marking the nearest upper level but not yet altering the overall set-up.
The 14-day RSI is 55.71, indicating neutral to mildly positive momentum, while the ADX at 20.40 suggests moderate trend strength that could increase if prices extend higher. The first resistance level to monitor is the Classic R1 pivot at $87.31; a daily close above this level could bring $90.67 into focus. On the downside, initial support lies at the $82.44 Classic Pivot, reinforced by the 100- and 200-day SMAs as key lower support levels (TradingView).
This analysis is for informational purposes only and does not constitute financial advice or a recommendation to buy or sell any instrument.
Merck & Company share price history
Merck shares have experienced a volatile two-year period, with prices rising through much of 2024 before reversing in 2025. The stock reached a recent high of $132.86 on 25 June 2024, ending the summer near $127 before declining sharply. By late September 2025, MRK had fallen to $78.68 as broader healthcare stocks came under pressure, a drop of nearly 41% from the prior year’s peak.
In recent months, the stock has recovered modestly, rebounding from those autumn lows to trade around $86.98 as of 29 October 2025. This remains around 32% lower year on year and 9.9% below the start of 2025. The movement underscores how quickly sector trends and sentiment can influence price performance, whether you’re monitoring short-term activity or observing longer-term trends.
Past performance is not a reliable indicator of future results.
Capital.com’s client sentiment for Merck CFDs
As of 29 October 2025, buyers account for 97.6% of open Merck share CFD positions, compared with 2.4% on the sell side, indicating a strong long bias of 95.2 percentage points. This snapshot represents current open positions on Capital.com and may change over time.
FAQ
Is Merck & Company a good stock to buy?
Merck & Company’s recent performance shows a modest recovery following a sharp decline in 2025, supported by steady demand for oncology products and generally stable fundamentals. However, analyst opinions remain mixed, with price targets differing across sources based on varying expectations for sector growth. This information is for reference only and does not constitute a recommendation to buy or sell. Past performance is not a reliable indicator of future results.
Could Merck & Company stock go up or down?
Analyst forecasts from several sources cluster between $95 and $116, though some project higher or lower outcomes depending on market conditions and product performance. As with any equity, the price may move in either direction, influenced by sector trends, earnings results and broader market sentiment. Analyst forecasts and predictions are often inaccurate. Past performance is not a reliable indicator of future results.
Should I invest in Merck & Company stock?
Investment decisions depend on personal risk tolerance, objectives and market knowledge. The information above offers neutral insight into recent performance and analyst expectations, but should not be taken as investment advice. Always consider the risks involved in CFD trading. Contracts for difference (CFDs) are traded on margin – leverage amplifies both profits and losses.
What affects Merck & Company’s share price?
Merck’s share price is influenced by earnings reports, product pipeline updates, regulatory announcements and overall healthcare sector trends. Broader macroeconomic factors such as interest rates and investor sentiment also contribute to price movement. Past performance is not a reliable indicator of future results.